Evidence map›Paper›PMID 33727310›Full record

ArticleCancer discovery2021

Surface Proteomics Reveals CD72 as a Target for

Matthew A Nix, Kamal Mandal, Huimin Geng, Neha Paranjape, Yu-Hsiu T Lin, Jose M Rivera, Makeba Marcoulis, Kristie L White, Jeffrey D Whitman, Sagar P Bapat and 11 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Matthew A NixDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7741-5368
Kamal MandalDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Huimin GengDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Neha ParanjapeDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Yu-Hsiu T LinDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Jose M RiveraDepartment of Pediatrics, University of California, San Francisco, San Francisco, California.
Makeba MarcoulisDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Kristie L WhiteDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Jeffrey D WhitmanDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-3502-5799
Sagar P BapatDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-4402-1511
Kevin R ParkerDepartment of Pathology, Stanford University, Stanford, California.ORCID 0000-0001-5532-238X
Jonathan RamirezCardiovascular Research Institute, University of California, San Francisco, San Francisco, California.
Anne DeucherDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Paul PhojanokongHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Veronica SteriHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.ORCID 0000-0003-2499-6618
Faranak FattahiCardiovascular Research Institute, University of California, San Francisco, San Francisco, California.
Byron C HannHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
Ansuman T SatpathyDepartment of Pathology, Stanford University, Stanford, California.ORCID 0000-0002-5167-537X
Aashish ManglikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, San Francisco, California.
Elliot StieglitzDepartment of Pediatrics, University of California, San Francisco, San Francisco, California.ORCID 0000-0001-7032-4623
Arun P WiitaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California. arun.wiita@ucsf.edu.ORCID 0000-0002-7465-6964
University of California, San Francisco · USUCSF Helen Diller Family Comprehensive Cancer Center · USStanford University · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
In vivo monitoring of oxidative protein folding through time-resolved quantitative mass spectrometryDP2GM123500 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2016 to 2016
$1.9M
Global Assessment of Myeloma Response to ChemotherapyK08CA184116 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2014 to 2018
$684k
Single cell epigenomics in cancer immunity and immunotherapyK08CA230188 · NCI · STANFORD UNIVERSITY · PI SATPATHY, ANSUMAN · 2018 to 2020
$448k
NCI NIH HHS K08 CA184116NCI NIH HHS K08 CA230188NCI NIH HHS P30 CA082103NIGMS NIH HHS DP2 GM123500
6 · The paper itself

Abstract

Alternative strategies are needed for patients with B-cell malignancy relapsing after CD19-targeted immunotherapy. Here, cell surface proteomics revealed CD72 as an optimal target for poor-prognosis

Indexed as

Antigens, CDAntigens, CD19Antigens, Differentiation, B-LymphocyteHumansImmunotherapy, AdoptivePrecursor B-Cell Lymphoblastic Leukemia-LymphomaProteomicsReceptors, Chimeric AntigenAntigens, CDAntigens, CD19Antigens, Differentiation, B-LymphocyteCD72 protein, humanReceptors, Chimeric Antigen

Identifiers

PMID33727310
PMCPMC8338785
OpenAlexW3137393431

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.